Speaker
Collin Zheng
(University of Sydney)
Description
Cytotoxic T-lymphocytes, commonly called killer T cells, are among our immune system’s most potent and well-understood weapons against cancer. However, checkpoint receptors such as CTLA-4 and PD-1 on the surfaces of T cells inhibit their activation and proliferation. These receptors can be blocked by antibody drugs, which pave the way for an anti-tumour immune response. We will present work-in-progress mathematical models on tumour-lymphocyte dynamics in the presence of checkpoint blockade therapy, discuss their clinical implications, and more broadly discuss the current modelling efforts in this area.
Primary author
Collin Zheng
(University of Sydney)
